CADL
Candel Therapeutics, Inc.$11.06+0.39 (+3.65%)Prev Close$10.68·MCap$830.2M·P/E—·Vol742.2K·Yield—
▲
Buys (12M)
1
$3.00M
▼
Sells (12M)
4
$3.55M
◆
Net Activity
Net Seller
$550.7K
●
Active Insiders
4
last 12 mo
Over the past 12 months, insider activity at Candel Therapeutics, Inc. (CADL) has been mixed between buying and selling, with 1 insider purchase totaling $3.00M and 4 insider sales totaling $3.55M. The most recent insider transaction was by Tak Paul Peter (director, officer: Chief Executive Officer), who sold $3.16M worth of shares on Sep 11, 2026. Candel Therapeutics, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $830.2M.
CADL Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Sep 11, 2026 | Tak Paul Peter | director, officer: Chief Executive Officer | Sell | 280,245 | $11.28 | $3.16M | 172,700-62% |
| Aug 19, 2026 | Tyagarajan Seshu | officer: Chief Technology Officer | Sell | 7,000 | $12.00 | $84.0K | 76,865 |
| Jul 1, 2026 | Tyagarajan Seshu | officer: Chief Technology Officer | Sell | 7,000 | $10.02 | $70.2K | 83,865 |
| Jul 1, 2026 | Barone Francesca | officer: Chief Scientific Officer | Sell | 23,447 | $10.06 | $235.8K | 77,362 |
| Feb 26, 2026 | Manning Paul B | director | Buy | 550,458 | $5.45 | $3.00M1.0% OS | 2,763,527 |
| Jul 28, 2025 | Nichols William Garrett | Chief Medical Officer | Sell | 937 | $6.98 | $6.5K | 0 |
| Jun 30, 2025 | Nichols William Garrett | Chief Medical Officer | Sell | 781 | $5.04 | $3.9K | 0 |
| Mar 18, 2025 | Barone Francesca | Chief Scientific Officer | Sell | 32,146 | $8.76 | $281.7K | 0 |
| Mar 18, 2025 | Nichols William Garrett | Chief Medical Officer | Sell | 45,316 | $8.76 | $397.0K | 0 |
| Mar 18, 2025 | Tak Paul Peter | Chief Executive Officer | Sell | 26,172 | $8.77 | $229.6K | 0 |
| Mar 17, 2025 | Schoch Charles | See Remarks | Sell | 5,000 | $8.83 | $44.2K | 0 |
| Mar 17, 2025 | Tyagarajan Seshu | Chief Technology Officer | Sell | 31,278 | $8.82 | $275.9K | 0 |
| Feb 21, 2025 | Aguilar-Cordova Estuardo | 10% Owner | Sell | 21,165 | $12.02 | $254.4K | 0 |
| Feb 10, 2025 | Aguilar-Cordova Estuardo | 10% Owner | Sell | 31,335 | $8.61 | $269.8K | 0 |
| Jan 15, 2025 | Barone Francesca | Chief Scientific Officer | Sell | 13,534 | $7.22 | $97.8K | 0 |
| Jan 15, 2025 | Nichols William Garrett | Chief Medical Officer | Sell | 10,428 | $7.23 | $75.3K | 0 |
| Jan 15, 2025 | Schoch Charles | See Remarks | Sell | 9,511 | $7.23 | $68.7K | 0 |
| Jan 15, 2025 | Tak Paul Peter | Chief Executive Officer | Sell | 21,704 | $7.22 | $156.8K | 0 |
| Jan 15, 2025 | Tyagarajan Seshu | Chief Technology Officer | Sell | 14,322 | $7.22 | $103.5K | 0 |
| Jan 8, 2025 | Barone Francesca | Chief Scientific Officer | Sell | 13,673 | $8.22 | $112.4K | 0 |
| Jan 8, 2025 | Nichols William Garrett | Chief Medical Officer | Sell | 10,799 | $8.22 | $88.7K | 0 |
| Jan 8, 2025 | Schoch Charles | See Remarks | Sell | 9,971 | $8.22 | $81.9K | 0 |
| Jan 8, 2025 | Tak Paul Peter | Chief Executive Officer | Sell | 21,172 | $8.22 | $174.0K | 0 |
| Jan 8, 2025 | Tyagarajan Seshu | Chief Technology Officer | Sell | 14,545 | $8.22 | $119.5K | 0 |
| Dec 26, 2024 | Aguilar-Cordova Estuardo | 10% Owner | Sell | 100,000 | $8.93 | $893.0K | 0 |
| Dec 20, 2024 | Aguilar-Cordova Estuardo | 10% Owner | Sell | 200,000 | $8.84 | $1.77M | 0 |
| Dec 16, 2024 | Manning Paul B | Director | Buy | 1,250,000 | $6.00 | $7.50M2.3% OS | 0 |
| Dec 11, 2024 | Aguilar-Cordova Estuardo | 10% Owner | Sell | 400,000 | $9.29 | $3.71M0.7% OS | 0 |
| Dec 4, 2024 | Aguilar-Cordova Estuardo | 10% Owner | Sell | 60,000 | $4.83 | $289.6K | 0 |
| Nov 29, 2024 | Barone Francesca | Chief Scientific Officer | Sell | 22,081 | $4.56 | $100.6K | 0 |
| Nov 29, 2024 | Nichols William Garrett | Chief Medical Officer | Sell | 13,935 | $4.56 | $63.5K | 0 |
| Nov 29, 2024 | Tak Paul Peter | Chief Executive Officer | Sell | 48,847 | $4.56 | $222.5K | 0 |
| Nov 29, 2024 | Tyagarajan Seshu | Chief Technology Officer | Sell | 20,392 | $4.56 | $92.9K | 0 |
| Nov 25, 2024 | Aguilar-Cordova Estuardo | 10% Owner | Sell | 20,000 | $4.97 | $99.4K | 0 |
| Nov 6, 2024 | Aguilar-Cordova Estuardo | 10% Owner | Sell | 22,500 | $5.15 | $115.8K | 0 |
| Oct 30, 2024 | Aguilar-Cordova Estuardo | 10% Owner | Sell | 21,000 | $5.31 | $111.6K | 0 |
| Oct 24, 2024 | Aguilar-Cordova Estuardo | 10% Owner | Sell | 30,929 | $5.57 | $172.3K | 0 |
| Oct 11, 2024 | Aguilar-Cordova Estuardo | 10% Owner | Sell | 40,412 | $6.03 | $243.8K | 0 |
| Oct 1, 2024 | Aguilar-Cordova Estuardo | 10% Owner | Sell | 35,002 | $6.93 | $242.6K | 0 |
| Jul 17, 2024 | Barone Francesca | Chief Scientific Officer | Sell | 14,051 | $6.47 | $90.9K | 0 |
| Jul 17, 2024 | Nichols William Garrett | Chief Medical Officer | Sell | 10,875 | $6.47 | $70.4K | 0 |
| Jul 17, 2024 | Schoch Charles | See Remarks | Sell | 9,884 | $6.47 | $64.0K | 0 |
| Jul 17, 2024 | Tak Paul Peter | Chief Executive Officer | Sell | 22,528 | $6.47 | $145.8K | 0 |
| Jul 17, 2024 | Tyagarajan Seshu | Chief Technology Officer | Sell | 14,851 | $6.47 | $96.1K | 0 |
| Jul 11, 2024 | Barone Francesca | Chief Scientific Officer | Sell | 12,645 | $5.97 | $75.5K | 0 |
| Jul 11, 2024 | Nichols William Garrett | Chief Medical Officer | Sell | 9,769 | $5.97 | $58.4K | 0 |
| Jul 11, 2024 | Schoch Charles | See Remarks | Sell | 8,897 | $5.97 | $53.1K | 0 |
| Jul 11, 2024 | Tak Paul Peter | Chief Executive Officer | Sell | 20,293 | $5.97 | $121.2K | 0 |
| Jul 11, 2024 | Tyagarajan Seshu | Chief Technology Officer | Sell | 13,330 | $5.97 | $79.6K | 0 |
| Nov 28, 2023 | Amello Jason | Chief Financial Officer | Sell | 20,153 | $0.90 | $18.1K | 0 |
Showing 1–50 of 68
1 / 2
CADL Insider Buying Activity
The following table shows recent insider purchases of Candel Therapeutics, Inc. (CADL) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Feb 26, 2026 | Manning Paul B | director | Buy | 550,458 | $5.45 | $3.00M1.0% OS | 2,763,527 |
| Dec 16, 2024 | Manning Paul B | Director | Buy | 1,250,000 | $6.00 | $7.50M2.3% OS | 0 |
CADL Insider Selling Activity
The following table shows recent insider sales of Candel Therapeutics, Inc. (CADL) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Sep 11, 2026 | Tak Paul Peter | director, officer: Chief Executive Officer | Sell | 280,245 | $11.28 | $3.16M | 172,700-62% |
| Aug 19, 2026 | Tyagarajan Seshu | officer: Chief Technology Officer | Sell | 7,000 | $12.00 | $84.0K | 76,865 |
| Jul 1, 2026 | Tyagarajan Seshu | officer: Chief Technology Officer | Sell | 7,000 | $10.02 | $70.2K | 83,865 |
| Jul 1, 2026 | Barone Francesca | officer: Chief Scientific Officer | Sell | 23,447 | $10.06 | $235.8K | 77,362 |
| Jul 28, 2025 | Nichols William Garrett | Chief Medical Officer | Sell | 937 | $6.98 | $6.5K | 0 |
| Jun 30, 2025 | Nichols William Garrett | Chief Medical Officer | Sell | 781 | $5.04 | $3.9K | 0 |
| Mar 18, 2025 | Barone Francesca | Chief Scientific Officer | Sell | 32,146 | $8.76 | $281.7K | 0 |
| Mar 18, 2025 | Nichols William Garrett | Chief Medical Officer | Sell | 45,316 | $8.76 | $397.0K | 0 |
| Mar 18, 2025 | Tak Paul Peter | Chief Executive Officer | Sell | 26,172 | $8.77 | $229.6K | 0 |
| Mar 17, 2025 | Schoch Charles | See Remarks | Sell | 5,000 | $8.83 | $44.2K | 0 |
| Mar 17, 2025 | Tyagarajan Seshu | Chief Technology Officer | Sell | 31,278 | $8.82 | $275.9K | 0 |
| Feb 21, 2025 | Aguilar-Cordova Estuardo | 10% Owner | Sell | 21,165 | $12.02 | $254.4K | 0 |
| Feb 10, 2025 | Aguilar-Cordova Estuardo | 10% Owner | Sell | 31,335 | $8.61 | $269.8K | 0 |
| Jan 15, 2025 | Barone Francesca | Chief Scientific Officer | Sell | 13,534 | $7.22 | $97.8K | 0 |
| Jan 15, 2025 | Nichols William Garrett | Chief Medical Officer | Sell | 10,428 | $7.23 | $75.3K | 0 |
| Jan 15, 2025 | Schoch Charles | See Remarks | Sell | 9,511 | $7.23 | $68.7K | 0 |
| Jan 15, 2025 | Tak Paul Peter | Chief Executive Officer | Sell | 21,704 | $7.22 | $156.8K | 0 |
| Jan 15, 2025 | Tyagarajan Seshu | Chief Technology Officer | Sell | 14,322 | $7.22 | $103.5K | 0 |
| Jan 8, 2025 | Barone Francesca | Chief Scientific Officer | Sell | 13,673 | $8.22 | $112.4K | 0 |
| Jan 8, 2025 | Nichols William Garrett | Chief Medical Officer | Sell | 10,799 | $8.22 | $88.7K | 0 |
| Jan 8, 2025 | Schoch Charles | See Remarks | Sell | 9,971 | $8.22 | $81.9K | 0 |
| Jan 8, 2025 | Tak Paul Peter | Chief Executive Officer | Sell | 21,172 | $8.22 | $174.0K | 0 |
| Jan 8, 2025 | Tyagarajan Seshu | Chief Technology Officer | Sell | 14,545 | $8.22 | $119.5K | 0 |
| Dec 26, 2024 | Aguilar-Cordova Estuardo | 10% Owner | Sell | 100,000 | $8.93 | $893.0K | 0 |
| Dec 20, 2024 | Aguilar-Cordova Estuardo | 10% Owner | Sell | 200,000 | $8.84 | $1.77M | 0 |
| Dec 11, 2024 | Aguilar-Cordova Estuardo | 10% Owner | Sell | 400,000 | $9.29 | $3.71M0.7% OS | 0 |
| Dec 4, 2024 | Aguilar-Cordova Estuardo | 10% Owner | Sell | 60,000 | $4.83 | $289.6K | 0 |
| Nov 29, 2024 | Barone Francesca | Chief Scientific Officer | Sell | 22,081 | $4.56 | $100.6K | 0 |
| Nov 29, 2024 | Nichols William Garrett | Chief Medical Officer | Sell | 13,935 | $4.56 | $63.5K | 0 |
| Nov 29, 2024 | Tak Paul Peter | Chief Executive Officer | Sell | 48,847 | $4.56 | $222.5K | 0 |
| Nov 29, 2024 | Tyagarajan Seshu | Chief Technology Officer | Sell | 20,392 | $4.56 | $92.9K | 0 |
| Nov 25, 2024 | Aguilar-Cordova Estuardo | 10% Owner | Sell | 20,000 | $4.97 | $99.4K | 0 |
| Nov 6, 2024 | Aguilar-Cordova Estuardo | 10% Owner | Sell | 22,500 | $5.15 | $115.8K | 0 |
| Oct 30, 2024 | Aguilar-Cordova Estuardo | 10% Owner | Sell | 21,000 | $5.31 | $111.6K | 0 |
| Oct 24, 2024 | Aguilar-Cordova Estuardo | 10% Owner | Sell | 30,929 | $5.57 | $172.3K | 0 |
| Oct 11, 2024 | Aguilar-Cordova Estuardo | 10% Owner | Sell | 40,412 | $6.03 | $243.8K | 0 |
| Oct 1, 2024 | Aguilar-Cordova Estuardo | 10% Owner | Sell | 35,002 | $6.93 | $242.6K | 0 |
| Jul 17, 2024 | Barone Francesca | Chief Scientific Officer | Sell | 14,051 | $6.47 | $90.9K | 0 |
| Jul 17, 2024 | Nichols William Garrett | Chief Medical Officer | Sell | 10,875 | $6.47 | $70.4K | 0 |
| Jul 17, 2024 | Schoch Charles | See Remarks | Sell | 9,884 | $6.47 | $64.0K | 0 |
| Jul 17, 2024 | Tak Paul Peter | Chief Executive Officer | Sell | 22,528 | $6.47 | $145.8K | 0 |
| Jul 17, 2024 | Tyagarajan Seshu | Chief Technology Officer | Sell | 14,851 | $6.47 | $96.1K | 0 |
| Jul 11, 2024 | Barone Francesca | Chief Scientific Officer | Sell | 12,645 | $5.97 | $75.5K | 0 |
| Jul 11, 2024 | Nichols William Garrett | Chief Medical Officer | Sell | 9,769 | $5.97 | $58.4K | 0 |
| Jul 11, 2024 | Schoch Charles | See Remarks | Sell | 8,897 | $5.97 | $53.1K | 0 |
| Jul 11, 2024 | Tak Paul Peter | Chief Executive Officer | Sell | 20,293 | $5.97 | $121.2K | 0 |
| Jul 11, 2024 | Tyagarajan Seshu | Chief Technology Officer | Sell | 13,330 | $5.97 | $79.6K | 0 |
| Nov 28, 2023 | Amello Jason | Chief Financial Officer | Sell | 20,153 | $0.90 | $18.1K | 0 |
CADL Insiders
Tak Paul Peter
director, officer: Chief Executive Officer
Bought $230.0KSold $4.25M
10 tradesLast: Sep 11, 2026
Tyagarajan Seshu
officer: Chief Technology Officer
Bought $25.1KSold $937.4K
10 tradesLast: Aug 19, 2026
Similar Stocks to CADL
VRTX
Vertex Pharmaceuticals Incorporated
$513.52-1.17%
$132.26B
REGN
Regeneron Pharmaceuticals, Inc.
$772.87-2.63%
$83.21B
MRNA
Moderna, Inc.
$142.93-2.49%
$57.13B
RVMD
Revolution Medicines, Inc.
$204.47-0.31%
$44.15B
INSM
Insmed Incorporated
$119.56-4.63%
$28.05B
INCY
Incyte Corporation
$121.65-0.43%
$24.62B
UTHR
United Therapeutics Corporation
$500.44-0.42%
$21.10B
NBIX
Neurocrine Biosciences, Inc.
$150.44-4.31%
$15.71B